Core Insights - Entera Bio Ltd. and OPKO Health, Inc. announced positive topline pharmacokinetic/pharmacodynamic results from their collaboration on a long-acting oxyntomodulin analog combined with Entera's N-Tab technology [1][5] - The program aims to develop the first oral dual agonist GLP-1/glucagon peptide for treating obesity and metabolic disorders [2] Company Developments - Entera and OPKO have completed in vivo proof-of-concept studies in rodent and pig models, showing significant systemic exposure and favorable pharmacokinetic profiles for oral OXM [6] - The oral OXM demonstrated a significant decrease in plasma glucose levels in a glucose tolerance test compared to a placebo [7] - OPKO's previous studies indicated that pegylated OXM led to significant weight loss and reductions in HbA1, triglycerides, and cholesterol levels in obese and diabetic patients [8] Market Context - The global weight management market was valued at $142.58 billion in 2022, with an expected CAGR of 9.94% from 2023 to 2030, indicating a growing opportunity for obesity treatments [4] - Entera and OPKO's market capitalizations are currently $70.14 million and $1.03 billion, respectively [4] Stock Performance - Following the announcement, ENTX shares fell by 1.5% to $1.93, while OPK shares remained nearly flat at $1.48 [3] - Over the past six months, ENTX and OPK shares have increased by 24.6% and 46.6%, respectively, contrasting with a 0.9% decline in the industry [9]
ENTX & OPK Stock May Gain Following Positive PK/PD Research Data